CTLA-4 gene polymorphisms and natural soluble CTLA-4 protein in psoriasis vulgaris.
CTLA-4 molecule is an important inhibitor of T-lymphocyte activation. Several single nucleotide polymorphisms (SNPs) in the CTLA-4 gene were found, and their associations with many human diseases were described. So far, however, such studies have not been performed in psoriasis vulgaris in Caucasoids. Therefore, we examined the distribution of three CTLA-4 SNPs: -1147C/T, -318C/T and +49 A/G in 116 patients with psoriasis vulgaris and 123 healthy blood donors using the polymerase chain reaction-restriction fragment length polymorphism method. For all three SNPs, the frequencies of alleles, genotypes and three-point haplotypes were very similar in patients and controls, suggesting no contribution of these genetic variants to psoriasis.
Luszczek
W
W
Laboratory of Immunogenetics, Department of Clinical Immunology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw.
Kubicka
W
W
Jasek
M
M
Baran
E
E
Cisło
M
M
Nockowski
P
P
Luczywo-Rudy
M
M
Wiśniewski
A
A
Nowak
I
I
Kuśnierczyk
P
P
D000328:Adult; D000368:Aged; D000483:Alleles; D017398:Alternative Splicing / Q000235:genetics; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000097:blood* / Q000235:genetics* / Q000627:therapeutic use; D060908:CTLA-4 Antigen; D005260:Female; D005787:Gene Frequency / Q000235:genetics; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D012150:Polymorphism, Restriction Fragment Length; D020641:Polymorphism, Single Nucleotide; D011237:Predictive Value of Tests; D020033:Protein Isoforms / Q000097:blood / Q000235:genetics / Q000627:therapeutic use; D011565:Psoriasis / Q000097:blood* / Q000188:drug therapy / Q000235:genetics*; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use
D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D020033:Protein Isoforms; D011994:Recombinant Proteins